文献速递艾滋病与性传播感染

免疫抑制与HIV病毒血症同美国及加拿大HIV感染者肛门癌风险的关联

Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada.
PubMed 文献 · Clin Infect Dis · 2020-01-01

研究发现,过去约8.5年至6个月的最低CD4计数和累积CD4低于200 cells/μL的时间比例是肛门癌风险的较好预测指标,支持严重且长期的HIV诱导免疫抑制促进肛门癌发生。

要点

  • 过去约8.5年至6个月的最低CD4<50 vs ≥500 cells/μL的肛门癌风险HR为13.4(95%CI 3.5-51.0)。
  • 过去约8.5年至4.5年CD4<200 cells/μL时间比例100% vs 0%的HR为3.1(95%CI 1.5-6.6)。
  • 最低CD4和累积CD4可作为识别高肛门癌风险HIV感染者的有用标志物。

核心结论

  • 结果支持严重且长期的HIV诱导免疫抑制促进肛门癌发生。
  • 最低CD4和累积CD4可能是识别高肛门癌风险HIV感染者的有用标志物。

研究设计与样本

  • 采用人口学调整、队列分层的Cox模型评估肛门癌风险与时间更新CD4和HIV RNA指标的关联。
  • 使用Akaike信息准则比较模型。

主要发现

  • 过去约8.5年至4.5年的累积和最低/峰值CD4或HIV RNA指标通常比近期相应指标更好地预测肛门癌风险。
  • 最佳模型包括过去约8.5年至6个月的最低CD4(<50 vs ≥500 cells/μL的HR为13.4,95%CI 3.5-51.0)。
  • 最佳模型还包括过去约8.5年至4.5年CD4<200 cells/μL的时间比例(100% vs 0%的HR为3.1,95%CI 1.5-6.6)。

临床怎么用

  • 对于HIV感染者,可考虑使用最低CD4和累积CD4水平来识别肛门癌高风险人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People living with human immunodeficiency virus (HIV; PLWH) have a markedly elevated anal cancer risk, largely due to loss of immunoregulatory control of oncogenic human papillomavirus infection. To better understand anal cancer development and prevention, we determined whether recent, past, cumulative, or nadir/peak CD4+ T-cell count (CD4) and/or HIV-1 RNA level (HIV RNA) best predict anal cancer risk. METHODS: We studied 102 777 PLWH during 1996-2014 from 21 cohorts participating in the North American AIDS Cohort Collaboration on Research and Design. Using demographics-adjusted, cohort-stratified Cox models, we assessed associations between anal cancer risk and various time-updated CD4 and HIV RNA measures, including cumulative and nadir/peak measures during prespecified moving time windows. We compared models using the Akaike information criterion. RESULTS: Cumulative and nadir/peak CD4 or HIV RNA measures from approximately 8.5 to 4.5 years in the past were generally better predictors for anal cancer risk than their corresponding more recent measures. However, the best model included CD4 nadir (ie, the lowest CD4) from approximately 8.5 years to 6 months in the past (hazard ratio [HR] for <50 vs ≥500 cells/µL, 13.4; 95% confidence interval [CI], 3.5-51.0) and proportion of time CD4 <200 cells/µL from approximately 8.5 to 4.5 years in the past (a cumulative measure; HR for 100% vs 0%, 3.1; 95% CI, 1.5-6.6). CONCLUSIONS: Our results are consistent with anal cancer promotion by severe, prolonged HIV-induced immunosuppression. Nadir and cumulative CD4 may represent useful markers for identifying PLWH at higher anal cancer risk.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hernández-Ramírez RU, Qin L, Lin H, et al. Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. Clin Infect Dis. 2020. PMID: 31044245. doi:10.1093/cid/ciz329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。